White matter lesion – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:00:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png White matter lesion – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Tolerability of Guanabenz in Children with Vanishing White Matter Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-guanabenz-in-children-with-vanishing-white-matter-disease/ Wed, 29 Apr 2026 14:59:02 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-guanabenz-in-children-with-vanishing-white-matter-disease/ This clinical trial is focused on studying a rare disease called Vanishing White Matter (VWM), which affects the brain and is known to start in early childhood. The study is investigating the use of a medication called Guanabenz, which is taken in capsule form. The purpose of the study is to explore how safe and tolerable Guanabenz is for children with VWM, as well as to understand how the body processes the medication.

Participants in the study will take Guanabenz capsules by mouth. The study will monitor participants over a period of time to observe any side effects and to gather information on how the medication is absorbed and broken down in the body. The study will also use MRI scans to look at changes in the brain and will track the overall health and survival of the participants.

The study aims to provide valuable information about the potential benefits and risks of using Guanabenz for treating VWM in children. This research could help in developing better treatment options for this rare condition in the future.

]]> Study on the Safety and Effects of Fosigotifator in Adults and Children with Vanishing White Matter Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fosigotifator-in-adults-and-children-with-vanishing-white-matter-disease/ Wed, 29 Apr 2026 14:56:54 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fosigotifator-in-adults-and-children-with-vanishing-white-matter-disease/ This clinical trial is focused on studying a rare condition known as Vanishing White Matter disease, which affects the brain and nervous system. The study will explore the effects of a treatment called Fosigotifator, which is being tested to see if it is safe and well-tolerated by both adults and children with this disease. Fosigotifator is a type of medication known as a prodrug, which means it is converted into an active form in the body, specifically into a compound called A-1684909.

The purpose of the study is to evaluate the safety and tolerability of Fosigotifator in patients with Vanishing White Matter disease. Participants will take the medication in the form of film-coated granules, which are taken orally. The study will involve regular visits to monitor the participants’ health, including checking vital signs, conducting physical exams, and performing brain scans using MRI technology. The study will also measure the levels of the active compound, A-1684909, in the blood and cerebrospinal fluid over time.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The trial will last for several weeks, with follow-up visits to ensure the safety and effectiveness of the treatment. This research aims to provide valuable insights into the potential benefits of Fosigotifator for individuals with Vanishing White Matter disease, contributing to the development of new treatment options for this challenging condition.

]]>